Transcripts involved in calcium signaling and telencephalic neuronal fate are altered in induced pluripotent stem cells from bipolar disorder patients

Translational Psychiatry

Volumn 4, Issue 3, 2014, Pages

  Chen, H M ^a   DeLong, C J ^a   Bame, M ^a   Rajapakse, I ^a   Herron, T J ^a   McInnis, M G ^a   O'Shea, K S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Calcium signaling; Disease modeling; Microarray analysis; Neuronal differentiation

Indexed keywords

CALCIUM; ION CHANNEL; LITHIUM; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EMX2; TRANSCRIPTION FACTOR NKX2.1; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ARTICLE; BIPOLAR DISORDER; CALCIUM SIGNALING; CELL FATE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; NERVE CELL DIFFERENTIATION; NERVOUS TISSUE; PLURIPOTENT STEM CELL; PROSPECTIVE STUDY; TELENCEPHALON;

EID: 84902508571     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.12     Document Type: Article

References (76)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-1757.
2. Murray CJ, Lopez AD. Evidence-based health policy-lessons fro the Global Burden of Disease Study. Science 1996; 274: 740-743.
3. McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003; 60: 497-502.
4. Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience 2009; 164: 331-343.
5. Liu Y, Blackwood DH, Caesar S, de Geus EJ, Farmer A, Ferreira MA et al. Wellcome Trust Case-Control Consortium. Meta-analysis of genome-wide association data of bipolar disorder and major depressive disorder. Mol Psychiatry 2011; 16: 2-4.
6. Gershon ES, Alliey-Rodriguez N, Liu C. After GWAS: searching for genetic risk for schizophrenia and bipolar disorder. Am J Psychiatry 2011; 168: 253-256.
7. Alsabban S, Rivera M, McGuffin P. Genome-wide searches for bipolar disorder genes. Curr Psychiatry Rep 2011; 13: 522-527.
8. Segurado R, Detera-Wadleigh SD, Levinson DF, Lewis CM, Gill M, Nurnberger JI Jr et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: bipolar disorder. Am J Hum Genet 2003; 73: 49-62.
9. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome wide analysis. The Lancet 2013; 381: 1371-1379.
10. Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008; 40: 1056-1058.
11. Green EK, Grozeva D, Jones I, Jones L, Kirov G, Caesar S et al. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry 2011; 15: 1016-1022.
12. Green EK, Hamshere M, Forty L, Gordon-Smith K, Fraser C, Russell E et al. Replication of bipolar disorder susceptibility alleles and identification of two novel genome-wide significant associations in a new bipolar disorder casecontrol sample. Mol Psychiatry 2012; 18: 1302-1307.
13. Perrier E, Pompei F, Ruberto G, Vassos E, Collier D, Frangou S. Initial evidence for the role of CACNA1C on subcortical brain morphology in patients with bipolar disorder. Eur Psychiatry 2011; 26: 135-137.
14. Poliak S, Peles E. The local differentiation of myelinated axons at nodes of Ranvier. Nat Rev Neurosci 2003; 4: 968-980.
15. Schulze TG, Detera-Wadleigh SD, Akula N, Gupta A, Kassem L, Steele J et al. Two variants in Ankyrin 3 (ANK3) are independent genetic risk factors for bipolar disorder. Mol Psychiatry 2009; 14: 487-491.
16. Zhang X, Lei K, Yuan X, Wu X, Zhuang Y, Xu T, Xu R, Han M. SUN1/2 and Syne/Nesprin-1/2 complexes connect centrosome to the nucleus during neurogenesis and neuronal migration in mice. Neuron 2009; 64: 173-187.
17. Soeiro-de-Souza MG, Bio DS, Dias VV, Vieta E, Machado-Vieira R, Moreno RA. The CACNA1C risk allele selectively impacts on executive function in bipolar type I disorder. Act Psychiatr Scand 2013; 128: 362-369.
18. Bearden CE, Hoffman KM, Cannon TD. The neuropsychology and neuroanatomy of bipolar affective disorder: a critical review. Bipolar Disord 2001; 3: 106-150.
19. DelBello MP, Adler CM, Strakowski SM. The neurophysiology of childhood and adolescent bipolar disorder. CNS Spectr 2006; 11: 298-311.
20. Kloos A, Weller EB, Weller RA. Biologic basis of bipolar disorder in children and adolescents. Curr Psychiatry Rep 2008; 10: 98-103.
21. Vawter MP, Freed WJ, Kleinman JE. Neuropathology of bipolar disorder. Biol Psychiatry 2000; 48: 486-504.
22. Beckmann H, Jakob H. Prenatal disturbances of nerve cell migration in the entorhinal region: a common vulnerability factor in functional psychoses? J Neural Transm Gen Sect 1991; 84: 155-164.
23. Laeng P, Pitts RL, Lemire AL, Drabik CE, Weiner A, Tang H et al. The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J Neurochem 2004; 91: 238-251.
24. Schloesser RJ, Chen G, Manji HK. Neurogenesis and neuroenhancement in the pathophysiology and treatment of bipolar disorder. Int Rev Neurobiol 2007; 77: 143-178.
25. Mehler MF, Gokhan S. Developmental mechanisms in the pathogenesis of neurodegenerative diseases. Prog Neurobiol 2001; 63: 337-363.
26. Wang H, Lei Q, Oosterveen T, Ericson J, Matise MP. Tcf/Lef repressors differentially regulate Shh-Gli target gene activation thresholds to generate progenitor patterning in the developing CNS. Development 2011; 138: 3711-3721.
27. Durnaoglu S, Genc S, Genc K. Patient-specific pluripotent stem cells in neurological diseases. Stem Cells Int 2011; 2011: 212487.
28. Gaspard N, van der Haeghen P. From stem cells to neural networks: recent advances and perspectives for neurodevelopmental disorders. Dev Med Child Neurol 2010; 53: 13-17.
29. Ebert AD, Yu J, Rose FF Jr, Mattis VB, Lorson CL, Thomson JA et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009; 457: 277-280.
30. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012; 482: 216-220.
31. Juopperi TA, Song H, Ming GL. Modeling neurological diseases using patientderived induced pluripotent stem cells. Future Neurol 2011; 6: 363-373.
32. Qiang L, Fujita R, Yamashita T, Angulo S, Rhinn H, Rhee D et al. Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. Cell 2011; 3: 359-371.
33. Urbach A, Bar-Nur O, Daley GQ, Benvenisty N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2010; 6: 407-411.
34. Zhang J, Lian Q, Zhou F, Sui L, Tan C, Mutalif RA et al. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 2011; 8: 31-45.
35. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011; 473: 221-225.
36. Lin M, Hrabovsky A, Pedrosa E, Wang T, Zheng D, Lachman HM. Allele-biased expression in differentiating human neurons: implications for neuropsychiatric disorders. PLoS ONE 2012; 7: e44017.
37. Pasca SP, Portmann T, Voineagu I, Yazawa M, Shcheglovitov A, Pasca AM et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 2011; 17: 1657-1662.
38. Robicsek O, Karry R, Petit I, Salman-Kesner N, Muller FJ, Klein E et al. Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenic patients. Mol Psychiatry 2013; 18: 1067-1076.
39. Langenecker SA, Saunders EF, Kade AM, Ransom MT, McInnis MG. Intermediate cognitive phenotypes in bipolar disorder. J Affect Disord 2010; 122: 285-293.
40. Nurnberger JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al. The diagnostic interview for genetic studies: Rationale, unique features, and training. Arch Gen Psychiatry 1994; 51: 849-859.
41. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells by defined factors. Cell 2007; 131: 861-872.
42. Maroof AM, Keros S, Tyson JA, Ying S-W, Ganat YM, Merkle FT et al. Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells. Cell Stem Cell 2013; 12: 559-572.
43. Nicholas CR, Chen J, Tang Y, Southwell DG, Chalmers N, Vogt D et al. Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. Cell Stem Cell 2013; 12: 573-586.
44. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protoc 2009; 4: 44-57.
45. Rajapakse I, Perlman MD, Scalzo D, Kooperberg C, Groudine M, Kosak ST. The emergence of lineage-specific chromosomal topologies from coordinate gene regulation. Proc Natl Acad Sci USA 2009; 106: 6679-6684.
46. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2012; 30: e36.
47. Lee P, Klos M, Bollensdorff C, Hou L, Ewart P, Kamp TJ, Zhang J et al. Simultaneous voltage and calcium mapping of genetically purified human induced pluripotent stem cell-derived cardiac myocyte monolayers. Circ Res 2012; 110: 1556-1563.
48. Mangale VS, Hirokawa KE, Satyaki PR, Gokulchandran N, Chikbire S, Subramanian L et al. Lhx2 selector activity specifies cortical identity and suppresses hippocampal organizer fate. Science 2008; 319: 304-309.
49. Goulburn AL, Alden D, Davis RP, Micallef SJ, Ng ES, Yu QC et al. A targeted NKX2.1 Hesc reporter line enables identification of human basal forebrain derivatives. Stem Cells 2011; 29: 462-473.
50. Jakovcevski I, Mayer N, Zecevic N. Multiple origins of human neocortical interneurons are supported by distinct expression of transcription factors. Cereb Cortex 2011; 21: 1771-1782.
51. Nat R Apostolova G Dechang G. Telencephalic neurogenesis versus telencephalic differentiation of pluripotent stem cells. In: Wislet-Gendebien, S. Trends in Cell Signaling Pathways in Neuronal Fate Decision. InTech: Rijeka, Croatia, 2013.
52. Sundberg M, Andersson PH, Akesson E, Odeberg J, Holmberg L, Inzunza J et al. Markers of pluripotency and differentiation in human neural precursor cells derived from embryonic stem cells and CNS tissue. Cell Transplant 2011; 20: 177-191.
53. Smith JR, Vallier L, Lupo G, Alexander M, Harris WA, Pedersen RA. Inhibition of activin/nodal signaling promotes specification of human embryonic stem cells into neuroectoderm. Dev Biol 2008; 313: 107-117.
54. Uezato A, Meador-Woodruff JH, McCullumsmith RE. Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia. Bipolar Disord 2009; 11: 711-725.
55. Cecil KM, DelBello MP, Sellars MC, Strakowski SM. Proton magnetic resonance spectroscopy of the frontal lobe and cerebellar vermis in children with a mood disorder and a familial risk for bipolar disorders. J Child Adolesc Psychopharmacol 2003; 13: 545-555.
56. Chen H, Wang N, Zhao X, Ross CA, O'Shea KS, McInnis MG. Gene expression alterations in bipolar disorder brains. Bipolar Disord 2013; 15: 177-187.
57. Brennand KJ, Simone A, Tran N, Gage FH. Modeling psychiatric disorders at the cellular and network levels. Mol Psychiatry 2012; 17: 1239-1253.
58. Mattis VB, Svendsen CN. Induced pluripotent stem cells: a new revolution for clinical neurology? Lancet 2011; 10: 383-394.
59. Berridge MJ. Dysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia. Prion 2013; 7: 2-13.
60. Van Meter AR, Moreira AL, Youngstrom EA. Meta-analysis of epidemiologic studies of pediatric bipolar disorder. J Clin Psychiatry 2011; 72: 1250-1256.
61. Howes OD, Falkenberg I. Early detection and intervention in bipolar affective disorder: targeting the development of the disorder. Curr Psychiatry Rep 2011; 13: 493-499.
62. Nasrallah HA. Neurodevelopmental aspects of bipolar affective disorder. Biol Psychiatry 1991; 29: 1-2.
63. Sigurdsson E, Fombonne E, Sayal K, Checkley S. Neurodevelopmental antecedents of early-onset bipolar affective disorder. Br J Psychiat 1999; 174: 121-127.
64. Marin O. Interneuron dysfunction in psychiatric disorders. Nat Rev Neurosci 2012; 13: 107-120.
65. Walker RM, Hill AE, Newman AC, Hamilton G, Torrance HS, Anderson SM et al. The DISC1 promoter: characterization and regulation by FOXP2. Hum Mol Genet 2012; 21: 2862-2872.
66. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006; 126: 1203-1217.
67. Kim AH, Reimers M, Maher B, Williamson V, McMichael O, McClay JL et al. MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res 2010; 124: 183-191.
68. Moreau MP, Bruse SE, David-Rus R, Buyske S, Brzustowicz LM. Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder. Biol Psychiatry 2011; 69: 188-193.
69. Chen H, Wang N, Burmeister M, McInnis MG. MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. Int J Neuropsychopharmacol 2009; 12: 975-981.
70. Rong H, Liu TB, Yang KJ, Yang HC, Wu DH, Liao CP et al. MicroRNA-134 plasma levels before and after treatment for bipolar mania. J Psychiatr Res 2011; 45: 92-95.
71. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharm 2009; 34: 1395-1405.
72. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-669.
73. Kritchevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS. A microRNA array reveals extensive regulation of microRNAs during brain development. RNA 2003; 9: 1274-1281.
74. Miska EA, Alvarez-Saavedra E, Townsend M, Yoshii A, Sestan N, Rakic P et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol 2004; 5: R68.
75. Smirnova L, Grafe A, Seiler A, Schumacher S, Nitsch R, Wulczyn FG. Regulation of miRNA expression during neural cell specification. Eur J Neurosci 2005; 21: 1469-1477.
76. Cheng HY, Papp JW, Varlamova O, Dziema H, Russell B, Curfman JP et al. micro-RNA modulation of circadian-clock period and entrainment. Neuron 2007; 54: 813-829.